Kymera gains FDA Fast Track for KT-621 as Gilead licenses KT-200
Kymera said the FDA granted Fast Track designation to KT-621 for moderate to severe eosinophilic asthma, while Gilead licensed KT-200 and triggered a $45 million milestone payment.
Small Molecule Therapeutics
MechanismRelated News
Zentalis selects 400 mg azenosertib regimen for Cyclin E1-positive ovarian cancer
Zentalis selected a 400 mg once-daily, 5-days-on/2-days-off azenosertib regimen for Cyclin E1-positive platinum-resistant ovarian cancer after a DENALI Phase 2 interim analysis. The regimen is planned for DENALI and ASPENOVA as the company pursues a potential accelerated approval pathway.